Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Large Cap | Pharmaceuticals & Drugs
1175.55
-10.90 (-0.92%)
< Home < Back

Dr Reddy’s Laboratories launches Finasteride tablets in US

Date: 03-01-2013

Dr Reddy’s Laboratories has launched Finasteride tablets (1 mg), a bioequivalent generic version of Propecia (Finasteride) tablets in the US market on January 02, 2013. The company’s abbreviated new drug application (ANDA) for Finasteride 1 mg tablets has been awarded a 180-day period of marketing exclusivity in the US on January 02, 2013.

The Propecia tablets brand has US sales of approximately $136 million MAT for the most recent twelve months ending October 2012, according to IMS Health. Dr Reddy’s Laboratories Finasteride tablets 1 mg is available in bottle counts of 30 and 90.

Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.